nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—PSIP1—neck—esophageal cancer	0.0282	0.115	CbGeAlD
L-DOPA—PSIP1—bronchus—esophageal cancer	0.0189	0.0773	CbGeAlD
L-DOPA—SLC7A8—neck—esophageal cancer	0.0186	0.076	CbGeAlD
L-DOPA—PSIP1—trachea—esophageal cancer	0.0169	0.0694	CbGeAlD
L-DOPA—PSIP1—digestive system—esophageal cancer	0.0146	0.0597	CbGeAlD
L-DOPA—PSIP1—lung—esophageal cancer	0.0122	0.0498	CbGeAlD
L-DOPA—Urine color abnormal—Capecitabine—esophageal cancer	0.0112	0.0365	CcSEcCtD
L-DOPA—SLC16A10—neck—esophageal cancer	0.011	0.0451	CbGeAlD
L-DOPA—Phlebitis—Carboplatin—esophageal cancer	0.0103	0.0335	CcSEcCtD
L-DOPA—SLC7A5—epithelium—esophageal cancer	0.00979	0.0401	CbGeAlD
L-DOPA—SLC7A5—bronchus—esophageal cancer	0.00964	0.0395	CbGeAlD
L-DOPA—SLC7A5—smooth muscle tissue—esophageal cancer	0.00943	0.0386	CbGeAlD
L-DOPA—SLC7A5—trachea—esophageal cancer	0.00866	0.0354	CbGeAlD
L-DOPA—PSIP1—lymph node—esophageal cancer	0.00833	0.0341	CbGeAlD
L-DOPA—SLC15A1—epithelium—esophageal cancer	0.00812	0.0333	CbGeAlD
L-DOPA—SLC7A8—lung—esophageal cancer	0.00802	0.0328	CbGeAlD
L-DOPA—Trismus—Capecitabine—esophageal cancer	0.00792	0.0258	CcSEcCtD
L-DOPA—SLC16A10—epithelium—esophageal cancer	0.00749	0.0307	CbGeAlD
L-DOPA—SLC7A5—digestive system—esophageal cancer	0.00745	0.0305	CbGeAlD
L-DOPA—Chromaturia—Capecitabine—esophageal cancer	0.0074	0.0241	CcSEcCtD
L-DOPA—DDC—lung—esophageal cancer	0.00694	0.0284	CbGeAlD
L-DOPA—SLC7A5—lung—esophageal cancer	0.00622	0.0255	CbGeAlD
L-DOPA—SLC15A1—digestive system—esophageal cancer	0.00618	0.0253	CbGeAlD
L-DOPA—Hoarseness—Capecitabine—esophageal cancer	0.00601	0.0196	CcSEcCtD
L-DOPA—Serum creatinine increased—Cisplatin—esophageal cancer	0.00583	0.019	CcSEcCtD
L-DOPA—SLC7A8—lymph node—esophageal cancer	0.00549	0.0225	CbGeAlD
L-DOPA—Dementia—Methotrexate—esophageal cancer	0.00479	0.0156	CcSEcCtD
L-DOPA—SLC16A10—lung—esophageal cancer	0.00476	0.0195	CbGeAlD
L-DOPA—DDC—lymph node—esophageal cancer	0.00475	0.0194	CbGeAlD
L-DOPA—Masoprocol—CYP19A1—esophageal cancer	0.00432	0.299	CrCbGaD
L-DOPA—Serum creatinine increased—Capecitabine—esophageal cancer	0.0043	0.014	CcSEcCtD
L-DOPA—Bacterial infection—Methotrexate—esophageal cancer	0.00426	0.0139	CcSEcCtD
L-DOPA—SLC7A5—lymph node—esophageal cancer	0.00425	0.0174	CbGeAlD
L-DOPA—Haemoglobin decreased—Capecitabine—esophageal cancer	0.00384	0.0125	CcSEcCtD
L-DOPA—Pain—Carboplatin—esophageal cancer	0.00373	0.0121	CcSEcCtD
L-DOPA—Blister—Capecitabine—esophageal cancer	0.00367	0.0119	CcSEcCtD
L-DOPA—Hiccups—Cisplatin—esophageal cancer	0.00358	0.0117	CcSEcCtD
L-DOPA—Coagulopathy—Capecitabine—esophageal cancer	0.00339	0.011	CcSEcCtD
L-DOPA—Memory impairment—Capecitabine—esophageal cancer	0.00337	0.011	CcSEcCtD
L-DOPA—SLC16A10—lymph node—esophageal cancer	0.00326	0.0133	CbGeAlD
L-DOPA—Aminosalicylic Acid—PTGS1—esophageal cancer	0.00323	0.224	CrCbGaD
L-DOPA—Dysphonia—Capecitabine—esophageal cancer	0.00321	0.0105	CcSEcCtD
L-DOPA—Phlebitis—Cisplatin—esophageal cancer	0.00302	0.00983	CcSEcCtD
L-DOPA—DRD2—lung—esophageal cancer	0.00301	0.0123	CbGeAlD
L-DOPA—Haemolytic anaemia—Cisplatin—esophageal cancer	0.00288	0.00938	CcSEcCtD
L-DOPA—Gait disturbance—Capecitabine—esophageal cancer	0.00271	0.00881	CcSEcCtD
L-DOPA—Hiccups—Capecitabine—esophageal cancer	0.00264	0.0086	CcSEcCtD
L-DOPA—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.0026	0.00847	CcSEcCtD
L-DOPA—Urinary incontinence—Capecitabine—esophageal cancer	0.00255	0.00831	CcSEcCtD
L-DOPA—Mesalazine—PTGS1—esophageal cancer	0.00254	0.176	CrCbGaD
L-DOPA—Blood creatinine increased—Cisplatin—esophageal cancer	0.00244	0.00794	CcSEcCtD
L-DOPA—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00238	0.00774	CcSEcCtD
L-DOPA—Cramp muscle—Cisplatin—esophageal cancer	0.00234	0.00763	CcSEcCtD
L-DOPA—Nasopharyngitis—Cisplatin—esophageal cancer	0.00233	0.00758	CcSEcCtD
L-DOPA—Phlebitis—Capecitabine—esophageal cancer	0.00223	0.00725	CcSEcCtD
L-DOPA—Sleep disorder—Capecitabine—esophageal cancer	0.00222	0.00721	CcSEcCtD
L-DOPA—Sweating increased—Cisplatin—esophageal cancer	0.00219	0.00713	CcSEcCtD
L-DOPA—CYP2D6—digestive system—esophageal cancer	0.00217	0.00888	CbGeAlD
L-DOPA—Vascular purpura—Capecitabine—esophageal cancer	0.00214	0.00698	CcSEcCtD
L-DOPA—Haemolytic anaemia—Capecitabine—esophageal cancer	0.00212	0.00692	CcSEcCtD
L-DOPA—Hot flush—Capecitabine—esophageal cancer	0.00205	0.00668	CcSEcCtD
L-DOPA—Menopausal symptoms—Capecitabine—esophageal cancer	0.00203	0.00662	CcSEcCtD
L-DOPA—Dermatitis bullous—Capecitabine—esophageal cancer	0.00201	0.00653	CcSEcCtD
L-DOPA—Purpura—Capecitabine—esophageal cancer	0.00199	0.00648	CcSEcCtD
L-DOPA—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00198	0.00644	CcSEcCtD
L-DOPA—Myocardial infarction—Cisplatin—esophageal cancer	0.00197	0.0064	CcSEcCtD
L-DOPA—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00197	0.0064	CcSEcCtD
L-DOPA—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00192	0.00624	CcSEcCtD
L-DOPA—Diplopia—Capecitabine—esophageal cancer	0.00192	0.00624	CcSEcCtD
L-DOPA—Pain in extremity—Capecitabine—esophageal cancer	0.00192	0.00624	CcSEcCtD
L-DOPA—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.0019	0.00619	CcSEcCtD
L-DOPA—Aminosalicylic Acid—PTGS2—esophageal cancer	0.00185	0.128	CrCbGaD
L-DOPA—Urinary retention—Capecitabine—esophageal cancer	0.00182	0.00594	CcSEcCtD
L-DOPA—Ataxia—Capecitabine—esophageal cancer	0.0018	0.00587	CcSEcCtD
L-DOPA—Blood creatinine increased—Capecitabine—esophageal cancer	0.0018	0.00585	CcSEcCtD
L-DOPA—Urinary tract disorder—Cisplatin—esophageal cancer	0.00178	0.00579	CcSEcCtD
L-DOPA—Urethral disorder—Cisplatin—esophageal cancer	0.00176	0.00574	CcSEcCtD
L-DOPA—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00175	0.0057	CcSEcCtD
L-DOPA—Nasopharyngitis—Capecitabine—esophageal cancer	0.00172	0.00558	CcSEcCtD
L-DOPA—Gastritis—Capecitabine—esophageal cancer	0.0017	0.00553	CcSEcCtD
L-DOPA—Flushing—Cisplatin—esophageal cancer	0.00167	0.00544	CcSEcCtD
L-DOPA—Dysphagia—Capecitabine—esophageal cancer	0.00166	0.0054	CcSEcCtD
L-DOPA—Sweating increased—Capecitabine—esophageal cancer	0.00161	0.00526	CcSEcCtD
L-DOPA—Angina pectoris—Capecitabine—esophageal cancer	0.00161	0.00526	CcSEcCtD
L-DOPA—Arrhythmia—Cisplatin—esophageal cancer	0.00161	0.00524	CcSEcCtD
L-DOPA—Alopecia—Cisplatin—esophageal cancer	0.00159	0.00518	CcSEcCtD
L-DOPA—Flatulence—Cisplatin—esophageal cancer	0.00154	0.00503	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00154	0.00502	CcSEcCtD
L-DOPA—Weight increased—Capecitabine—esophageal cancer	0.00151	0.00491	CcSEcCtD
L-DOPA—Muscle spasms—Cisplatin—esophageal cancer	0.00151	0.0049	CcSEcCtD
L-DOPA—Weight decreased—Capecitabine—esophageal cancer	0.0015	0.00488	CcSEcCtD
L-DOPA—Vision blurred—Cisplatin—esophageal cancer	0.00148	0.00481	CcSEcCtD
L-DOPA—Depression—Capecitabine—esophageal cancer	0.00147	0.0048	CcSEcCtD
L-DOPA—Tremor—Cisplatin—esophageal cancer	0.00147	0.00478	CcSEcCtD
L-DOPA—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00146	0.00474	CcSEcCtD
L-DOPA—Ill-defined disorder—Cisplatin—esophageal cancer	0.00145	0.00473	CcSEcCtD
L-DOPA—Mesalazine—PTGS2—esophageal cancer	0.00145	0.1	CrCbGaD
L-DOPA—Myocardial infarction—Capecitabine—esophageal cancer	0.00145	0.00472	CcSEcCtD
L-DOPA—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00145	0.00472	CcSEcCtD
L-DOPA—Anaemia—Cisplatin—esophageal cancer	0.00145	0.00472	CcSEcCtD
L-DOPA—Urinary tract infection—Capecitabine—esophageal cancer	0.00144	0.00468	CcSEcCtD
L-DOPA—Malaise—Cisplatin—esophageal cancer	0.00141	0.0046	CcSEcCtD
L-DOPA—Leukopenia—Cisplatin—esophageal cancer	0.0014	0.00457	CcSEcCtD
L-DOPA—Agranulocytosis—Capecitabine—esophageal cancer	0.00138	0.00449	CcSEcCtD
L-DOPA—Convulsion—Cisplatin—esophageal cancer	0.00136	0.00442	CcSEcCtD
L-DOPA—Ataxia—Methotrexate—esophageal cancer	0.00134	0.00437	CcSEcCtD
L-DOPA—Haemoglobin—Capecitabine—esophageal cancer	0.00133	0.00434	CcSEcCtD
L-DOPA—Rhinitis—Capecitabine—esophageal cancer	0.00133	0.00433	CcSEcCtD
L-DOPA—Anxiety—Cisplatin—esophageal cancer	0.00133	0.00433	CcSEcCtD
L-DOPA—Haemorrhage—Capecitabine—esophageal cancer	0.00133	0.00432	CcSEcCtD
L-DOPA—Hypoaesthesia—Capecitabine—esophageal cancer	0.00132	0.0043	CcSEcCtD
L-DOPA—Discomfort—Cisplatin—esophageal cancer	0.00132	0.00429	CcSEcCtD
L-DOPA—Urinary tract disorder—Capecitabine—esophageal cancer	0.00131	0.00427	CcSEcCtD
L-DOPA—Urethral disorder—Capecitabine—esophageal cancer	0.0013	0.00423	CcSEcCtD
L-DOPA—Oedema—Cisplatin—esophageal cancer	0.00128	0.00416	CcSEcCtD
L-DOPA—Thrombocytopenia—Cisplatin—esophageal cancer	0.00125	0.00408	CcSEcCtD
L-DOPA—Hyperhidrosis—Cisplatin—esophageal cancer	0.00124	0.00402	CcSEcCtD
L-DOPA—Flushing—Capecitabine—esophageal cancer	0.00123	0.00401	CcSEcCtD
L-DOPA—Anorexia—Cisplatin—esophageal cancer	0.00122	0.00397	CcSEcCtD
L-DOPA—Hypotension—Cisplatin—esophageal cancer	0.0012	0.00389	CcSEcCtD
L-DOPA—Arrhythmia—Capecitabine—esophageal cancer	0.00119	0.00386	CcSEcCtD
L-DOPA—Alopecia—Capecitabine—esophageal cancer	0.00117	0.00382	CcSEcCtD
L-DOPA—Mental disorder—Capecitabine—esophageal cancer	0.00116	0.00378	CcSEcCtD
L-DOPA—Paraesthesia—Cisplatin—esophageal cancer	0.00115	0.00374	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00115	0.00373	CcSEcCtD
L-DOPA—Dyspnoea—Cisplatin—esophageal cancer	0.00114	0.00371	CcSEcCtD
L-DOPA—Flatulence—Capecitabine—esophageal cancer	0.00114	0.00371	CcSEcCtD
L-DOPA—Dysgeusia—Capecitabine—esophageal cancer	0.00113	0.00368	CcSEcCtD
L-DOPA—Back pain—Capecitabine—esophageal cancer	0.00112	0.00364	CcSEcCtD
L-DOPA—Decreased appetite—Cisplatin—esophageal cancer	0.00111	0.00362	CcSEcCtD
L-DOPA—Muscle spasms—Capecitabine—esophageal cancer	0.00111	0.00362	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.0011	0.00359	CcSEcCtD
L-DOPA—Depression—Methotrexate—esophageal cancer	0.0011	0.00357	CcSEcCtD
L-DOPA—Pain—Cisplatin—esophageal cancer	0.00109	0.00356	CcSEcCtD
L-DOPA—Vision blurred—Capecitabine—esophageal cancer	0.00109	0.00354	CcSEcCtD
L-DOPA—Tremor—Capecitabine—esophageal cancer	0.00108	0.00352	CcSEcCtD
L-DOPA—Ill-defined disorder—Capecitabine—esophageal cancer	0.00107	0.00349	CcSEcCtD
L-DOPA—Anaemia—Capecitabine—esophageal cancer	0.00107	0.00348	CcSEcCtD
L-DOPA—Liothyronine—ABCB1—esophageal cancer	0.00106	0.0734	CrCbGaD
L-DOPA—Feeling abnormal—Cisplatin—esophageal cancer	0.00105	0.00343	CcSEcCtD
L-DOPA—Malaise—Capecitabine—esophageal cancer	0.00104	0.00339	CcSEcCtD
L-DOPA—Syncope—Capecitabine—esophageal cancer	0.00104	0.00337	CcSEcCtD
L-DOPA—Leukopenia—Capecitabine—esophageal cancer	0.00103	0.00337	CcSEcCtD
L-DOPA—Agranulocytosis—Methotrexate—esophageal cancer	0.00103	0.00334	CcSEcCtD
L-DOPA—Palpitations—Capecitabine—esophageal cancer	0.00102	0.00332	CcSEcCtD
L-DOPA—Loss of consciousness—Capecitabine—esophageal cancer	0.00102	0.00331	CcSEcCtD
L-DOPA—Cough—Capecitabine—esophageal cancer	0.00101	0.00328	CcSEcCtD
L-DOPA—Hypertension—Capecitabine—esophageal cancer	0.000997	0.00325	CcSEcCtD
L-DOPA—Haemoglobin—Methotrexate—esophageal cancer	0.000993	0.00323	CcSEcCtD
L-DOPA—Haemorrhage—Methotrexate—esophageal cancer	0.000988	0.00322	CcSEcCtD
L-DOPA—Chest pain—Capecitabine—esophageal cancer	0.000983	0.0032	CcSEcCtD
L-DOPA—Anxiety—Capecitabine—esophageal cancer	0.00098	0.00319	CcSEcCtD
L-DOPA—Urinary tract disorder—Methotrexate—esophageal cancer	0.000976	0.00318	CcSEcCtD
L-DOPA—Discomfort—Capecitabine—esophageal cancer	0.000972	0.00316	CcSEcCtD
L-DOPA—Urethral disorder—Methotrexate—esophageal cancer	0.000968	0.00315	CcSEcCtD
L-DOPA—Dry mouth—Capecitabine—esophageal cancer	0.000962	0.00313	CcSEcCtD
L-DOPA—Confusional state—Capecitabine—esophageal cancer	0.000951	0.00309	CcSEcCtD
L-DOPA—Oedema—Capecitabine—esophageal cancer	0.000943	0.00307	CcSEcCtD
L-DOPA—Hypersensitivity—Cisplatin—esophageal cancer	0.000942	0.00307	CcSEcCtD
L-DOPA—Shock—Capecitabine—esophageal cancer	0.000928	0.00302	CcSEcCtD
L-DOPA—Thrombocytopenia—Capecitabine—esophageal cancer	0.000923	0.003	CcSEcCtD
L-DOPA—Asthenia—Cisplatin—esophageal cancer	0.000918	0.00299	CcSEcCtD
L-DOPA—Hyperhidrosis—Capecitabine—esophageal cancer	0.000911	0.00297	CcSEcCtD
L-DOPA—Anorexia—Capecitabine—esophageal cancer	0.000899	0.00293	CcSEcCtD
L-DOPA—Hypotension—Capecitabine—esophageal cancer	0.000881	0.00287	CcSEcCtD
L-DOPA—Diarrhoea—Cisplatin—esophageal cancer	0.000875	0.00285	CcSEcCtD
L-DOPA—Alopecia—Methotrexate—esophageal cancer	0.000873	0.00284	CcSEcCtD
L-DOPA—Mental disorder—Methotrexate—esophageal cancer	0.000865	0.00282	CcSEcCtD
L-DOPA—Insomnia—Capecitabine—esophageal cancer	0.000853	0.00278	CcSEcCtD
L-DOPA—Paraesthesia—Capecitabine—esophageal cancer	0.000847	0.00276	CcSEcCtD
L-DOPA—Dysgeusia—Methotrexate—esophageal cancer	0.000842	0.00274	CcSEcCtD
L-DOPA—Dyspnoea—Capecitabine—esophageal cancer	0.000841	0.00274	CcSEcCtD
L-DOPA—Back pain—Methotrexate—esophageal cancer	0.000832	0.00271	CcSEcCtD
L-DOPA—Dyspepsia—Capecitabine—esophageal cancer	0.00083	0.0027	CcSEcCtD
L-DOPA—Decreased appetite—Capecitabine—esophageal cancer	0.00082	0.00267	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000814	0.00265	CcSEcCtD
L-DOPA—Vomiting—Cisplatin—esophageal cancer	0.000813	0.00265	CcSEcCtD
L-DOPA—Fatigue—Capecitabine—esophageal cancer	0.000813	0.00265	CcSEcCtD
L-DOPA—Vision blurred—Methotrexate—esophageal cancer	0.00081	0.00264	CcSEcCtD
L-DOPA—Rash—Cisplatin—esophageal cancer	0.000806	0.00263	CcSEcCtD
L-DOPA—Constipation—Capecitabine—esophageal cancer	0.000806	0.00262	CcSEcCtD
L-DOPA—Pain—Capecitabine—esophageal cancer	0.000806	0.00262	CcSEcCtD
L-DOPA—Dermatitis—Cisplatin—esophageal cancer	0.000806	0.00262	CcSEcCtD
L-DOPA—Ill-defined disorder—Methotrexate—esophageal cancer	0.000798	0.0026	CcSEcCtD
L-DOPA—Anaemia—Methotrexate—esophageal cancer	0.000795	0.00259	CcSEcCtD
L-DOPA—Feeling abnormal—Capecitabine—esophageal cancer	0.000777	0.00253	CcSEcCtD
L-DOPA—Malaise—Methotrexate—esophageal cancer	0.000775	0.00252	CcSEcCtD
L-DOPA—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000771	0.00251	CcSEcCtD
L-DOPA—Leukopenia—Methotrexate—esophageal cancer	0.00077	0.00251	CcSEcCtD
L-DOPA—Nausea—Cisplatin—esophageal cancer	0.00076	0.00247	CcSEcCtD
L-DOPA—Cough—Methotrexate—esophageal cancer	0.00075	0.00244	CcSEcCtD
L-DOPA—Urticaria—Capecitabine—esophageal cancer	0.000749	0.00244	CcSEcCtD
L-DOPA—Abdominal pain—Capecitabine—esophageal cancer	0.000745	0.00243	CcSEcCtD
L-DOPA—Convulsion—Methotrexate—esophageal cancer	0.000745	0.00243	CcSEcCtD
L-DOPA—Chest pain—Methotrexate—esophageal cancer	0.000732	0.00238	CcSEcCtD
L-DOPA—Discomfort—Methotrexate—esophageal cancer	0.000723	0.00235	CcSEcCtD
L-DOPA—Confusional state—Methotrexate—esophageal cancer	0.000708	0.0023	CcSEcCtD
L-DOPA—Hypersensitivity—Capecitabine—esophageal cancer	0.000695	0.00226	CcSEcCtD
L-DOPA—Thrombocytopenia—Methotrexate—esophageal cancer	0.000687	0.00224	CcSEcCtD
L-DOPA—Hyperhidrosis—Methotrexate—esophageal cancer	0.000678	0.00221	CcSEcCtD
L-DOPA—Asthenia—Capecitabine—esophageal cancer	0.000676	0.0022	CcSEcCtD
L-DOPA—Anorexia—Methotrexate—esophageal cancer	0.000669	0.00218	CcSEcCtD
L-DOPA—Pruritus—Capecitabine—esophageal cancer	0.000667	0.00217	CcSEcCtD
L-DOPA—Hypotension—Methotrexate—esophageal cancer	0.000656	0.00213	CcSEcCtD
L-DOPA—Diarrhoea—Capecitabine—esophageal cancer	0.000645	0.0021	CcSEcCtD
L-DOPA—Insomnia—Methotrexate—esophageal cancer	0.000635	0.00207	CcSEcCtD
L-DOPA—Paraesthesia—Methotrexate—esophageal cancer	0.00063	0.00205	CcSEcCtD
L-DOPA—Dyspnoea—Methotrexate—esophageal cancer	0.000626	0.00204	CcSEcCtD
L-DOPA—Somnolence—Methotrexate—esophageal cancer	0.000624	0.00203	CcSEcCtD
L-DOPA—Dizziness—Capecitabine—esophageal cancer	0.000623	0.00203	CcSEcCtD
L-DOPA—Dyspepsia—Methotrexate—esophageal cancer	0.000618	0.00201	CcSEcCtD
L-DOPA—Decreased appetite—Methotrexate—esophageal cancer	0.00061	0.00199	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000606	0.00197	CcSEcCtD
L-DOPA—Fatigue—Methotrexate—esophageal cancer	0.000605	0.00197	CcSEcCtD
L-DOPA—Pain—Methotrexate—esophageal cancer	0.0006	0.00195	CcSEcCtD
L-DOPA—Vomiting—Capecitabine—esophageal cancer	0.000599	0.00195	CcSEcCtD
L-DOPA—Rash—Capecitabine—esophageal cancer	0.000594	0.00194	CcSEcCtD
L-DOPA—Dermatitis—Capecitabine—esophageal cancer	0.000594	0.00193	CcSEcCtD
L-DOPA—Headache—Capecitabine—esophageal cancer	0.000591	0.00192	CcSEcCtD
L-DOPA—Feeling abnormal—Methotrexate—esophageal cancer	0.000578	0.00188	CcSEcCtD
L-DOPA—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000574	0.00187	CcSEcCtD
L-DOPA—Nausea—Capecitabine—esophageal cancer	0.00056	0.00182	CcSEcCtD
L-DOPA—Urticaria—Methotrexate—esophageal cancer	0.000558	0.00182	CcSEcCtD
L-DOPA—Abdominal pain—Methotrexate—esophageal cancer	0.000555	0.00181	CcSEcCtD
L-DOPA—Hypersensitivity—Methotrexate—esophageal cancer	0.000517	0.00168	CcSEcCtD
L-DOPA—Asthenia—Methotrexate—esophageal cancer	0.000504	0.00164	CcSEcCtD
L-DOPA—Pruritus—Methotrexate—esophageal cancer	0.000497	0.00162	CcSEcCtD
L-DOPA—Diarrhoea—Methotrexate—esophageal cancer	0.00048	0.00156	CcSEcCtD
L-DOPA—Dizziness—Methotrexate—esophageal cancer	0.000464	0.00151	CcSEcCtD
L-DOPA—Vomiting—Methotrexate—esophageal cancer	0.000446	0.00145	CcSEcCtD
L-DOPA—Rash—Methotrexate—esophageal cancer	0.000443	0.00144	CcSEcCtD
L-DOPA—Dermatitis—Methotrexate—esophageal cancer	0.000442	0.00144	CcSEcCtD
L-DOPA—Headache—Methotrexate—esophageal cancer	0.00044	0.00143	CcSEcCtD
L-DOPA—Nausea—Methotrexate—esophageal cancer	0.000417	0.00136	CcSEcCtD
L-DOPA—DRD3—Signaling Pathways—WIF1—esophageal cancer	0.000179	0.000413	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CXCL2—esophageal cancer	0.000179	0.000412	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—SST—esophageal cancer	0.000178	0.00041	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PDE4D—esophageal cancer	0.000177	0.000409	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CXCL2—esophageal cancer	0.000176	0.000407	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—AKAP13—esophageal cancer	0.000176	0.000406	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—SST—esophageal cancer	0.000176	0.000405	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—GHRL—esophageal cancer	0.000175	0.000403	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PFN1—esophageal cancer	0.000174	0.000402	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—GHRL—esophageal cancer	0.000174	0.0004	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—GHRL—esophageal cancer	0.000171	0.000395	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—XIAP—esophageal cancer	0.000169	0.00039	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—GNG7—esophageal cancer	0.000169	0.000389	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CSNK1A1—esophageal cancer	0.000168	0.000387	CbGpPWpGaD
L-DOPA—DDC—Metabolism—HMOX1—esophageal cancer	0.000167	0.000386	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—ANXA1—esophageal cancer	0.000166	0.000383	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CSNK1A1—esophageal cancer	0.000166	0.000382	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000165	0.000381	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—ANXA1—esophageal cancer	0.000164	0.000378	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—SST—esophageal cancer	0.000162	0.000373	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ADCYAP1—esophageal cancer	0.000162	0.000372	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PDE4D—esophageal cancer	0.000161	0.000371	CbGpPWpGaD
L-DOPA—DDC—Metabolism—ABCB1—esophageal cancer	0.000161	0.00037	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CTNNA1—esophageal cancer	0.00016	0.000368	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—SST—esophageal cancer	0.00016	0.000368	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CXCL2—esophageal cancer	0.000159	0.000366	CbGpPWpGaD
L-DOPA—PSIP1—Disease—PIK3CA—esophageal cancer	0.000159	0.000365	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—GHRL—esophageal cancer	0.000158	0.000363	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PFN1—esophageal cancer	0.000157	0.000362	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ELMO1—esophageal cancer	0.000157	0.000361	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—TP53—esophageal cancer	0.000157	0.000361	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—GHRL—esophageal cancer	0.000156	0.000358	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PFN1—esophageal cancer	0.000155	0.000357	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—GNG7—esophageal cancer	0.000153	0.000353	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AKAP13—esophageal cancer	0.000153	0.000353	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—EP300—esophageal cancer	0.000149	0.000343	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CXCL2—esophageal cancer	0.000149	0.000343	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PSME2—esophageal cancer	0.000149	0.000342	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PSME1—esophageal cancer	0.000149	0.000342	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ANXA1—esophageal cancer	0.000148	0.000341	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—WWOX—esophageal cancer	0.000148	0.00034	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SST—esophageal cancer	0.000144	0.000331	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000141	0.000326	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ELMO1—esophageal cancer	0.000141	0.000325	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—TP53—esophageal cancer	0.000141	0.000325	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FKBP1A—esophageal cancer	0.000141	0.000324	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—GHRL—esophageal cancer	0.00014	0.000323	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NOTCH3—esophageal cancer	0.00014	0.000323	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PDE4D—esophageal cancer	0.00014	0.000323	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ELMO1—esophageal cancer	0.000139	0.000321	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—TP53—esophageal cancer	0.000139	0.000321	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—ANXA1—esophageal cancer	0.000138	0.000318	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—FBXW7—esophageal cancer	0.000138	0.000318	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AKAP13—esophageal cancer	0.000138	0.000318	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—WIF1—esophageal cancer	0.000137	0.000316	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AKAP13—esophageal cancer	0.000136	0.000313	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CXCL2—esophageal cancer	0.000135	0.000311	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—SST—esophageal cancer	0.000134	0.00031	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—GNG7—esophageal cancer	0.000133	0.000307	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SLC52A3—esophageal cancer	0.000133	0.000305	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—BLVRB—esophageal cancer	0.000133	0.000305	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—GHRL—esophageal cancer	0.000131	0.000302	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000127	0.000293	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CSNK1A1—esophageal cancer	0.000127	0.000292	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PDE4D—esophageal cancer	0.000126	0.00029	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NOTCH2—esophageal cancer	0.000126	0.00029	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—ANXA1—esophageal cancer	0.000126	0.000289	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000126	0.000289	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—XIAP—esophageal cancer	0.000125	0.000288	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PDE4D—esophageal cancer	0.000124	0.000287	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—SST—esophageal cancer	0.000122	0.000281	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—GNG7—esophageal cancer	0.00012	0.000276	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—GHRL—esophageal cancer	0.000119	0.000274	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PFN1—esophageal cancer	0.000119	0.000273	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—GNG7—esophageal cancer	0.000118	0.000273	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CTNNA1—esophageal cancer	0.000118	0.000272	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CXCL2—esophageal cancer	0.000117	0.00027	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SLC10A2—esophageal cancer	0.000113	0.00026	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CA1—esophageal cancer	0.000113	0.00026	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—XIAP—esophageal cancer	0.000112	0.000259	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TGFBR2—esophageal cancer	0.000112	0.000257	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—XIAP—esophageal cancer	0.000111	0.000255	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PSME1—esophageal cancer	0.00011	0.000253	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PSME2—esophageal cancer	0.00011	0.000253	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ANXA1—esophageal cancer	0.000109	0.000251	CbGpPWpGaD
L-DOPA—DDC—Metabolism—CREBBP—esophageal cancer	0.000107	0.000247	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ELMO1—esophageal cancer	0.000106	0.000245	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—TP53—esophageal cancer	0.000106	0.000245	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CTNNA1—esophageal cancer	0.000106	0.000245	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SST—esophageal cancer	0.000106	0.000245	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CXCL2—esophageal cancer	0.000106	0.000243	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SMAD4—esophageal cancer	0.000106	0.000243	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CTNNA1—esophageal cancer	0.000105	0.000242	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CXCL2—esophageal cancer	0.000104	0.00024	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKAP13—esophageal cancer	0.000104	0.00024	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NOTCH3—esophageal cancer	0.000103	0.000238	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—GHRL—esophageal cancer	0.000103	0.000238	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CA2—esophageal cancer	0.000103	0.000237	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—FBXW7—esophageal cancer	0.000102	0.000234	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PSME1—esophageal cancer	9.87e-05	0.000227	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PSME2—esophageal cancer	9.87e-05	0.000227	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ANXA1—esophageal cancer	9.82e-05	0.000226	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PSME1—esophageal cancer	9.74e-05	0.000224	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PSME2—esophageal cancer	9.74e-05	0.000224	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ANXA1—esophageal cancer	9.69e-05	0.000223	CbGpPWpGaD
L-DOPA—DDC—Metabolism—NOS3—esophageal cancer	9.61e-05	0.000221	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HIST1H2BM—esophageal cancer	9.61e-05	0.000221	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ADH7—esophageal cancer	9.58e-05	0.000221	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PLCE1—esophageal cancer	9.58e-05	0.000221	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SST—esophageal cancer	9.56e-05	0.00022	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PDE4D—esophageal cancer	9.52e-05	0.000219	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SST—esophageal cancer	9.43e-05	0.000217	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—GHRL—esophageal cancer	9.31e-05	0.000215	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NOTCH3—esophageal cancer	9.31e-05	0.000215	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NOTCH2—esophageal cancer	9.28e-05	0.000214	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NOTCH3—esophageal cancer	9.19e-05	0.000212	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—GHRL—esophageal cancer	9.19e-05	0.000212	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—FBXW7—esophageal cancer	9.16e-05	0.000211	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GNG7—esophageal cancer	9.05e-05	0.000209	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—FBXW7—esophageal cancer	9.04e-05	0.000208	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PTGS2—esophageal cancer	8.79e-05	0.000203	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HIF1A—esophageal cancer	8.64e-05	0.000199	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—XIAP—esophageal cancer	8.48e-05	0.000195	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ADH1B—esophageal cancer	8.4e-05	0.000194	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NOTCH2—esophageal cancer	8.35e-05	0.000192	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—KDR—esophageal cancer	8.26e-05	0.00019	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NOTCH2—esophageal cancer	8.24e-05	0.00019	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TGFBR2—esophageal cancer	8.23e-05	0.00019	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—TYMP—esophageal cancer	8.03e-05	0.000185	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CTNNA1—esophageal cancer	8.02e-05	0.000185	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCL2—esophageal cancer	7.98e-05	0.000184	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP26A1—esophageal cancer	7.81e-05	0.00018	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SMAD4—esophageal cancer	7.79e-05	0.000179	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NOTCH1—esophageal cancer	7.78e-05	0.000179	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ALOX15—esophageal cancer	7.61e-05	0.000175	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PSME1—esophageal cancer	7.45e-05	0.000172	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PSME2—esophageal cancer	7.45e-05	0.000172	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ANXA1—esophageal cancer	7.42e-05	0.000171	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TGFBR2—esophageal cancer	7.41e-05	0.000171	CbGpPWpGaD
L-DOPA—DDC—Metabolism—EP300—esophageal cancer	7.31e-05	0.000168	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TGFBR2—esophageal cancer	7.31e-05	0.000168	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTO1—esophageal cancer	7.26e-05	0.000167	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—TPI1—esophageal cancer	7.26e-05	0.000167	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SST—esophageal cancer	7.21e-05	0.000166	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CREBBP—esophageal cancer	7.05e-05	0.000163	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GHRL—esophageal cancer	7.03e-05	0.000162	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NOTCH3—esophageal cancer	7.03e-05	0.000162	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SMAD4—esophageal cancer	7.01e-05	0.000162	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ALDOB—esophageal cancer	6.96e-05	0.00016	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—EGFR—esophageal cancer	6.93e-05	0.00016	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SMAD4—esophageal cancer	6.92e-05	0.000159	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FBXW7—esophageal cancer	6.92e-05	0.000159	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GAPDH—esophageal cancer	6.7e-05	0.000154	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CRABP1—esophageal cancer	6.64e-05	0.000153	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—PIK3CA—esophageal cancer	6.63e-05	0.000153	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HIF1A—esophageal cancer	6.37e-05	0.000147	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GNG7—esophageal cancer	6.32e-05	0.000146	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NOS3—esophageal cancer	6.32e-05	0.000146	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NOTCH2—esophageal cancer	6.31e-05	0.000145	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KDR—esophageal cancer	6.1e-05	0.00014	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—PIK3CA—esophageal cancer	6.02e-05	0.000139	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ALDH2—esophageal cancer	5.92e-05	0.000136	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ERBB2—esophageal cancer	5.91e-05	0.000136	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NOTCH1—esophageal cancer	5.74e-05	0.000132	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HIF1A—esophageal cancer	5.74e-05	0.000132	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HIF1A—esophageal cancer	5.66e-05	0.00013	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTT1—esophageal cancer	5.63e-05	0.00013	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TGFBR2—esophageal cancer	5.59e-05	0.000129	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP2A6—esophageal cancer	5.56e-05	0.000128	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KDR—esophageal cancer	5.49e-05	0.000126	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KDR—esophageal cancer	5.41e-05	0.000125	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PIK3CA—esophageal cancer	5.41e-05	0.000125	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SMAD4—esophageal cancer	5.3e-05	0.000122	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTGS1—esophageal cancer	5.28e-05	0.000122	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ENO1—esophageal cancer	5.28e-05	0.000122	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCND1—esophageal cancer	5.22e-05	0.00012	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CREBBP—esophageal cancer	5.21e-05	0.00012	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PSME2—esophageal cancer	5.2e-05	0.00012	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PSME1—esophageal cancer	5.2e-05	0.00012	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NOTCH1—esophageal cancer	5.17e-05	0.000119	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—EGFR—esophageal cancer	5.12e-05	0.000118	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NOTCH1—esophageal cancer	5.1e-05	0.000118	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CDKN1A—esophageal cancer	5.05e-05	0.000116	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—PIK3CA—esophageal cancer	4.89e-05	0.000113	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—EP300—esophageal cancer	4.8e-05	0.000111	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CREBBP—esophageal cancer	4.69e-05	0.000108	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NOS3—esophageal cancer	4.66e-05	0.000107	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CREBBP—esophageal cancer	4.62e-05	0.000107	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—EGFR—esophageal cancer	4.61e-05	0.000106	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—EGFR—esophageal cancer	4.54e-05	0.000105	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP1B1—esophageal cancer	4.49e-05	0.000103	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—PIK3CA—esophageal cancer	4.44e-05	0.000102	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—PIK3CA—esophageal cancer	4.4e-05	0.000101	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ERBB2—esophageal cancer	4.36e-05	0.0001	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—PIK3CA—esophageal cancer	4.34e-05	0.0001	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HIF1A—esophageal cancer	4.33e-05	9.98e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP19A1—esophageal cancer	4.22e-05	9.72e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NOS3—esophageal cancer	4.2e-05	9.67e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MYC—esophageal cancer	4.19e-05	9.65e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KDR—esophageal cancer	4.14e-05	9.55e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NOS3—esophageal cancer	4.14e-05	9.54e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—EGFR—esophageal cancer	4.1e-05	9.43e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PIK3CA—esophageal cancer	4e-05	9.21e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PIK3CA—esophageal cancer	3.94e-05	9.09e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ERBB2—esophageal cancer	3.93e-05	9.04e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NOTCH1—esophageal cancer	3.9e-05	8.99e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ERBB2—esophageal cancer	3.87e-05	8.92e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCND1—esophageal cancer	3.85e-05	8.88e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—HMOX1—esophageal cancer	3.85e-05	8.87e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CDKN1A—esophageal cancer	3.73e-05	8.59e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ABCB1—esophageal cancer	3.69e-05	8.51e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PIK3CA—esophageal cancer	3.55e-05	8.19e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EP300—esophageal cancer	3.55e-05	8.17e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CREBBP—esophageal cancer	3.54e-05	8.15e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—EGFR—esophageal cancer	3.48e-05	8.01e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCND1—esophageal cancer	3.47e-05	7.99e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TP53—esophageal cancer	3.44e-05	7.92e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCND1—esophageal cancer	3.42e-05	7.88e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CDKN1A—esophageal cancer	3.35e-05	7.73e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PIK3CA—esophageal cancer	3.32e-05	7.66e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CDKN1A—esophageal cancer	3.31e-05	7.63e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EP300—esophageal cancer	3.19e-05	7.35e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NOS3—esophageal cancer	3.17e-05	7.3e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EP300—esophageal cancer	3.15e-05	7.26e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MYC—esophageal cancer	3.09e-05	7.12e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EGFR—esophageal cancer	3.02e-05	6.96e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CA—esophageal cancer	3.02e-05	6.95e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ERBB2—esophageal cancer	2.96e-05	6.83e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MYC—esophageal cancer	2.78e-05	6.41e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MYC—esophageal cancer	2.74e-05	6.32e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EGFR—esophageal cancer	2.72e-05	6.27e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EGFR—esophageal cancer	2.68e-05	6.18e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CA—esophageal cancer	2.62e-05	6.04e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCND1—esophageal cancer	2.62e-05	6.03e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TP53—esophageal cancer	2.54e-05	5.85e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CDKN1A—esophageal cancer	2.53e-05	5.84e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CREBBP—esophageal cancer	2.47e-05	5.69e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EP300—esophageal cancer	2.41e-05	5.55e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CA—esophageal cancer	2.36e-05	5.44e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CA—esophageal cancer	2.33e-05	5.37e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TP53—esophageal cancer	2.28e-05	5.26e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TP53—esophageal cancer	2.25e-05	5.19e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NOS3—esophageal cancer	2.21e-05	5.09e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MYC—esophageal cancer	2.1e-05	4.84e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EGFR—esophageal cancer	2.05e-05	4.73e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTGS2—esophageal cancer	2.02e-05	4.66e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CA—esophageal cancer	1.78e-05	4.11e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TP53—esophageal cancer	1.72e-05	3.97e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—EP300—esophageal cancer	1.68e-05	3.87e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CA—esophageal cancer	1.24e-05	2.87e-05	CbGpPWpGaD
